{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T05:59:18Z","timestamp":1668232758443},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pheochromocytomas (PCC) are rare and functional neuroendocrine tumors developing from adrenal chromaffin cells. Predicting malignant behavior especially in the absence of metastasis can be quite challenging even in the era of improved understanding of the molecular mechanisms involved in PCCs. Currently, two histopathological grading systems Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) and Grading of Adrenal Pheochromocytoma and Paraganglioma (GAPP) score are used in clinical practice, but these are subject to significant interobserver variability. Some of the most useful clinical factors associated with malignancy are large size ([4\u20135 cm), and genetic features such as presence of SDHB germline mutations. Local invasion is uncommon in PCC and metastasis seen in 10 to 17% but higher in germline mutations and when this occurs management can be challenging. Here, we report on a case with challenges faced by the pathologist and clinicians alike in diagnosis and management of PCC recurrence.<\/jats:p>","DOI":"10.1186\/s12957-022-02817-6","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T05:16:32Z","timestamp":1668143792000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Locally invasive recurrence or metastasis of pheochromocytoma into the liver?\u2014clinicopathological challenges"],"prefix":"10.1186","volume":"20","author":[{"given":"Sarah S.","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James W. K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujith","family":"Wijerethne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shridhar Ganpathi","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Hue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nga Min","family":"En","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajeev","family":"Parameswaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,11]]},"reference":[{"issue":"12","key":"2817_CR1","first-page":"802","volume":"58","author":"CM Beard","year":"1983","unstructured":"Beard CM, et al. Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc. 1983;58(12):802\u20134.","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"2817_CR2","volume":"12","author":"S Venugopal","year":"2020","unstructured":"Venugopal S, Chhabria M, Quartuccio M. Recurrence of Pheochromocytoma With Metastases After Resection of Primary Tumor. Cureus. 2020;12(5):e8328.","journal-title":"Cureus"},{"issue":"5","key":"2817_CR3","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1210\/jc.2018-01707","volume":"104","author":"LM Gruber","year":"2019","unstructured":"Gruber LM, et al. Pheochromocytoma Characteristics and Behavior Differ Depending on Method of Discovery. J Clin Endocrinol Metab. 2019;104(5):1386\u201393.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2817_CR4","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1097\/RCT.0b013e31829cbecf","volume":"37","author":"AR Oshmyansky","year":"2013","unstructured":"Oshmyansky AR, et al. Serendipity in the diagnosis of pheochromocytoma. J Comput Assist Tomogr. 2013;37(5):820\u20133.","journal-title":"J Comput Assist Tomogr"},{"issue":"6","key":"2817_CR5","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1210\/endrev\/bnaa008","volume":"41","author":"M Sherlock","year":"2020","unstructured":"Sherlock M, et al. Adrenal Incidentaloma. Endocr Rev. 2020;41(6):775\u2013820.","journal-title":"Endocr Rev"},{"issue":"8","key":"2817_CR6","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1097\/HJH.0000000000002438","volume":"38","author":"JWM Lenders","year":"2020","unstructured":"Lenders JWM, et al. Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens. 2020;38(8):1443\u201356.","journal-title":"J Hypertens"},{"issue":"4","key":"2817_CR7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s11154-007-9055-z","volume":"8","author":"WF Young Jr","year":"2007","unstructured":"Young WF Jr. Adrenal causes of hypertension: pheochromocytoma and primary aldosteronism. Rev Endocr Metab Disord. 2007;8(4):309\u201320.","journal-title":"Rev Endocr Metab Disord"},{"issue":"6","key":"2817_CR8","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1056\/NEJMra1806651","volume":"381","author":"HPH Neumann","year":"2019","unstructured":"Neumann HPH, Young WF Jr, Eng C. Pheochromocytoma and Paraganglioma. N Engl J Med. 2019;381(6):552\u201365.","journal-title":"N Engl J Med"},{"issue":"2","key":"2817_CR9","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","volume":"31","author":"L Fishbein","year":"2017","unstructured":"Fishbein L, et al. Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell. 2017;31(2):181\u201393.","journal-title":"Cancer Cell"},{"issue":"1","key":"2817_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.trecan.2017.11.001","volume":"4","author":"I Jochmanova","year":"2018","unstructured":"Jochmanova I, Pacak K. Genomic Landscape of Pheochromocytoma and Paraganglioma. Trends Cancer. 2018;4(1):6\u20139.","journal-title":"Trends Cancer"},{"issue":"20","key":"2817_CR11","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.1093\/hmg\/ddr324","volume":"20","author":"N Burnichon","year":"2011","unstructured":"Burnichon N, et al. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum Mol Genet. 2011;20(20):3974\u201385.","journal-title":"Hum Mol Genet"},{"issue":"2","key":"2817_CR12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1210\/endrev\/bnab019","volume":"43","author":"S N\u00f6lting","year":"2021","unstructured":"N\u00f6lting S, et al. Personalized Management of Pheochromocytoma and Paraganglioma. Endocr Rev. 2021;43(2):199\u2013239.","journal-title":"Endocr Rev"},{"issue":"3","key":"2817_CR13","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s12022-017-9484-5","volume":"28","author":"AK-Y Lam","year":"2017","unstructured":"Lam AK-Y. Update on adrenal tumours in 2017 World Health Organization (WHO) of Endocrine Tumours. Endocr Pathol. 2017;28(3):213\u201327.","journal-title":"Endocr Pathol"},{"issue":"5","key":"2817_CR14","doi-asserted-by":"publisher","first-page":"e1937","DOI":"10.1210\/clinem\/dgaa982","volume":"106","author":"D Granberg","year":"2021","unstructured":"Granberg D, Juhlin CC, Falhammar H. Metastatic Pheochromocytomas and Abdominal Paragangliomas. J Clin Endocrinol Metab. 2021;106(5):e1937\u201352.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2817_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s11864-020-00787-z","volume":"21","author":"M Ilanchezhian","year":"2020","unstructured":"Ilanchezhian M, et al. Emerging Treatments for Advanced\/Metastatic Pheochromocytoma and Paraganglioma. Curr Treat Options in Oncol. 2020;21(11):85.","journal-title":"Curr Treat Options in Oncol"},{"key":"2817_CR16","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1186\/1471-2407-14-523","volume":"14","author":"J Schovanek","year":"2014","unstructured":"Schovanek J, et al. The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study. BMC Cancer. 2014;14:523.","journal-title":"BMC Cancer"},{"issue":"11","key":"2817_CR17","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1016\/j.ejca.2011.07.016","volume":"48","author":"G Eisenhofer","year":"2012","unstructured":"Eisenhofer G, et al. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer. 2012;48(11):1739\u201349.","journal-title":"Eur J Cancer"},{"issue":"5","key":"2817_CR18","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-16-0033","volume":"174","author":"PF Plouin","year":"2016","unstructured":"Plouin PF, et al. European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur J Endocrinol. 2016;174(5):G1\u2013g10.","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2817_CR19","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1097\/00000478-200205000-00002","volume":"26","author":"LD Thompson","year":"2002","unstructured":"Thompson LD. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol. 2002;26(5):551\u201366.","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"2817_CR20","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1530\/ERC-13-0494","volume":"21","author":"N Kimura","year":"2014","unstructured":"Kimura N, et al. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr Relat Cancer. 2014;21(3):405\u201314.","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"2817_CR21","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.surg.2008.02.007","volume":"143","author":"VE Strong","year":"2008","unstructured":"Strong VE, et al. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle\/apoptosis gene expression analysis. Surgery. 2008;143(6):759\u201368.","journal-title":"Surgery"},{"issue":"6","key":"2817_CR22","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrendo.2014.41","volume":"10","author":"G Eisenhofer","year":"2014","unstructured":"Eisenhofer G, Tischler AS. Neuroendocrine cancer. Closing the GAPP on predicting metastases. Nat Rev Endocrinol. 2014;10(6):315\u20136.","journal-title":"Nat Rev Endocrinol"},{"issue":"9","key":"2817_CR23","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1055\/s-0029-1231025","volume":"41","author":"R Adjall\u00e9","year":"2009","unstructured":"Adjall\u00e9 R, et al. Treatment of malignant pheochromocytoma. Horm Metab Res. 2009;41(9):687\u201396.","journal-title":"Horm Metab Res"},{"issue":"4","key":"2817_CR24","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.eprac.2020.09.015","volume":"27","author":"Y Cui","year":"2021","unstructured":"Cui Y, et al. Differences in Clinical Manifestations and Tumor Features Between Metastatic Pheochromocytoma\/Paraganglioma Patients With and Without Germline SDHB Mutation. Endocr Pract. 2021;27(4):348\u201353.","journal-title":"Endocr Pract"},{"issue":"4","key":"2817_CR25","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1677\/ERC-08-0049","volume":"15","author":"HJ Timmers","year":"2008","unstructured":"Timmers HJ, et al. Metastases but not cardiovascular mortality reduces life expectancy following surgical resection of apparently benign pheochromocytoma. Endocr Relat Cancer. 2008;15(4):1127\u201333.","journal-title":"Endocr Relat Cancer"},{"issue":"9","key":"2817_CR26","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.jvir.2011.06.016","volume":"22","author":"JF McBride","year":"2011","unstructured":"McBride JF, et al. Minimally invasive treatment of metastatic pheochromocytoma and paraganglioma: efficacy and safety of radiofrequency ablation and cryoablation therapy. J Vasc Interv Radiol. 2011;22(9):1263\u201370.","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"2817_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.adro.2017.11.002","volume":"3","author":"W Breen","year":"2018","unstructured":"Breen W, et al. External beam radiation therapy for advanced\/unresectable malignant paraganglioma and pheochromocytoma. Adv Radiat Oncol. 2018;3(1):25\u20139.","journal-title":"Adv Radiat Oncol"},{"key":"2817_CR28","doi-asserted-by":"crossref","unstructured":"Kohlenberg J, et al. Efficacy and Safety of Ablative Therapy in the Treatment of Patients with Metastatic Pheochromocytoma and Paraganglioma. Cancers (Basel). 2019;11(2):195.","DOI":"10.3390\/cancers11020195"},{"issue":"5","key":"2817_CR29","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1507\/endocrj.43.511","volume":"43","author":"S Teno","year":"1996","unstructured":"Teno S, et al. Acutely exacerbated hypertension and increased inflammatory signs due to radiation treatment for metastatic pheochromocytoma. Endocr J. 1996;43(5):511\u20136.","journal-title":"Endocr J"},{"issue":"25","key":"2817_CR30","doi-asserted-by":"publisher","first-page":"4162","DOI":"10.1200\/JCO.2008.21.3496","volume":"27","author":"S Gonias","year":"2009","unstructured":"Gonias S, et al. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol. 2009;27(25):4162\u20138.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2817_CR31","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/MED.0000000000000544","volume":"27","author":"C Jimenez","year":"2020","unstructured":"Jimenez C, N\u00fa\u00f1ez R, Wendt R. High-specific-activity iodine 131 metaiodobenzylguanidine for the treatment of metastatic pheochromocytoma or paraganglioma: a novel therapy for an orphan disease. Curr Opin Endocrinol Diabetes Obes. 2020;27(3):162\u20139.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"11","key":"2817_CR32","doi-asserted-by":"publisher","first-page":"R627","DOI":"10.1530\/ERC-19-0165","volume":"26","author":"D Ta\u00efeb","year":"2019","unstructured":"Ta\u00efeb D, et al. Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups. Endocr Relat Cancer. 2019;26(11):R627\u2013r652.","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"2817_CR33","first-page":"334","volume":"52","author":"F Forrer","year":"2008","unstructured":"Forrer F, et al. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. Q J Nucl Med Mol Imaging. 2008;52(4):334\u201340.","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"5","key":"2817_CR34","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/cen.12542","volume":"81","author":"ND Niemeijer","year":"2014","unstructured":"Niemeijer ND, et al. Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis. Clin Endocrinol. 2014;81(5):642\u201351.","journal-title":"Clin Endocrinol"},{"issue":"2","key":"2817_CR35","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s12020-009-9219-6","volume":"36","author":"J He","year":"2009","unstructured":"He J, et al. Successful chemotherapy of hepatic metastases in a case of succinate dehydrogenase subunit B-related paraganglioma. Endocrine. 2009;36(2):189\u201393.","journal-title":"Endocrine"},{"issue":"12","key":"2817_CR36","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/s41416-019-0474-x","volume":"120","author":"GM O'Kane","year":"2019","unstructured":"O'Kane GM, et al. A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial. Br J Cancer. 2019;120(12):1113\u20139.","journal-title":"Br J Cancer"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-022-02817-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-022-02817-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-022-02817-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T05:17:25Z","timestamp":1668143845000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-022-02817-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,11]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2817"],"URL":"https:\/\/doi.org\/10.1186\/s12957-022-02817-6","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,11]]},"assertion":[{"value":"18 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethical approval required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"360"}}